Mechanism of Action
gp41 6-Helix Bundle Inhibition
After HIV gp120 binds CD4 and co-receptors on T cells, gp41 undergoes conformational changes: the N-terminal heptad repeat (NHR) trimer forms a coiled-coil that exposes the CHR regions. Normally, the CHR regions fold back onto the NHR to form the 6-helix bundle, pulling viral and cellular membranes together for fusion. Enfuvirtide mimics the CHR region and competitively binds the NHR coiled-coil in trans, preventing the endogenous CHR from forming the fusion-active 6-helix bundle. This leaves gp41 in a non-fusogenic pre-hairpin conformation.
Unique Entry-Stage Mechanism
Enfuvirtide acts extracellularly at the viral entry step, before viral RNA enters the cell. This mechanism is completely distinct from all other antiretroviral drug classes (RTIs, PIs, INSTIs, entry inhibitors like maraviroc) and retains activity against viruses resistant to those classes. The entry-stage mechanism also means HIV must be actively trying to fuse when enfuvirtide is present, "use-dependent" inhibition - which is relevant to pharmacodynamic considerations.
Research Summary
Phase 3 TORO Trials, FDA Approval
FDA ApprovedTORO 1 and TORO 2 (T-20 versus Optimized Regimen Only) Phase 3 trials enrolled treatment-experienced HIV-1 patients with documented resistance to at least one drug from each of three ARV classes. Adding enfuvirtide to optimized background therapy achieved viral load reduction >1 log10 in significantly more patients versus optimized therapy alone. These pivotal trials demonstrated enfuvirtide utility in salvage therapy, leading to FDA approval on March 13, 2003 (first biologic peptide antiviral).
Resistance and Limitations
FDA ApprovedResistance emerges through mutations in the gp41 NHR region (positions 36-45), particularly G36D/S, V38A/M/E, Q40H, N43D, N42T, L45M. These mutations reduce enfuvirtide binding affinity. Resistance develops more slowly than to most oral ARVs, typically over months. The main clinical limitations are inconvenient twice-daily subcutaneous injection and high incidence of injection site reactions (98% of patients). New generation fusion inhibitors (albuvirtide, long-acting) are being developed.
Calculate your Enfuvirtide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HIV-1 treatment (approved) | 90 mg SC twice daily | Twice daily | Subcutaneous injection |
| Pediatric (weight-based) | 2 mg/kg SC twice daily (max 90 mg) | Twice daily | Subcutaneous injection |
Requires reconstitution with sterile water before use. Must be rotated injection sites.
Interactions
Safety Profile
Injection site reactions (ISRs) are universal (98%), typically induration, erythema, cysts, and nodules that are generally mild-moderate. Eosinophilia and elevated liver enzymes occur in ~5%. Hypersensitivity reactions are rare (<1%) but can be severe. No significant drug-drug interactions through CYP450. Unlike many ARVs, enfuvirtide is not associated with metabolic complications (dyslipidemia, lipodystrophy).
References
- [1]Lalezari JP, et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 348(22), 2175-2185.
- [2]Kilby JM, et al. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med, 4(11), 1302-1307.